Legislation of the 119th Congress

The bill expands legal remedies, defenses, and access to representation for people who were trafficked—potentially reducing incarceration and improving reintegration—while imposing meaningful new burdens and costs on courts and government agencies and creating privacy, evidentiary, and funding trade-offs that may limit or delay some benefits.

1. house
3. senate
5. president

The bill strengthens and clarifies federal coverage of sexually explicit depictions of minors to better protect children and aid prosecutions, but it increases risks of over-criminalization, free‑speech chill, and higher enforcement costs.

1. house
3. senate
5. president

The bill strengthens protections for child victims and gives prosecutors clearer tools and longer reach to pursue creators and distributors of obscene child-sex materials, but it also increases risks to defendants' procedural rights (pretrial detention, evidence access), expands registry burdens, and raises costs from broader federal enforcement.

1. senate
3. house
5. president

The bill directs substantial new funding and program changes to expand prevention, treatment, and support for substance use and behavioral health—potentially improving access and capacity—while increasing federal spending, administrative requirements, and some legal/privacy risks that could complicate implementation and unevenly affect access across states.

1. house
3. senate
5. president

The bill strengthens federal criminal protections and prosecutorial clarity for sexual contact with minors and in federal custody — improving victim protection and deterrence — but does so while narrowing certain defenses, risking retroactive exposure for past conduct, and imposing modest administrative burdens on federal agencies.

1. senate
3. house
5. president

The bill strengthens U.S. tools, transparency, and targeted authorities to disrupt fentanyl supply chains while preserving ordinary goods trade, but it risks diplomatic escalation, new compliance and administrative costs, and constraints on some executive sanctions options.

1. house
3. senate
5. president

1. senate
3. house
5. president

The bill improves maritime safety and Coast Guard readiness by clarifying onboard drug offenses and expanding naloxone access and oversight, but it risks narrowing prosecutorial reach, adding costs, raising privacy concerns, and leaving some units with inadequate naloxone access.

1. house
3. senate
5. president

The bill reduces poisoning risk and creates clearer rules while preserving regulated uses of sodium nitrite, but it may raise compliance costs, restrict access for some lawful users, and cut revenue for niche small businesses.

1. house
3. senate
5. president

The bill strengthens public safety and prosecutorial clarity by treating all fentanyl-related substances as a single, immediately enforceable class — improving deterrence and reducing new-analog circulation — but does so at the cost of higher research and administrative burdens, potential disruptions to legitimate medical access, expanded criminal exposure, and increased enforcement costs.

1. house
3. senate
5. president

The bill raises public and institutional awareness about fentanyl—supporting naloxone access, targeted outreach, and law-enforcement/public-health coordination—but risks skewing resources and policy toward enforcement, border controls, and punitive responses that could undercut treatment and harm-reduction strategies.

1. senate

The resolution strengthens U.S. ability to hold corrupt actors accountable and support prosecution and sanctions, but that stance risks straining bilateral cooperation and could produce humanitarian costs from conditioned aid and increased domestic political friction.

1. senate

The resolution raises public awareness and promotes safe disposal and local prevention efforts around the overdose/fentanyl crisis, but it is largely symbolic and risks emphasizing enforcement and stigma over expanding evidence‑based treatment and harm‑reduction services.

1. senate

The resolution raises public awareness about the scale of substance use and recovery—supporting prevention and expanded treatment—but could prompt greater federal spending and risk increasing stigma for people who use drugs or are in recovery.

1. senate

The resolution raises public awareness and encourages education about fentanyl—potentially helping families and youth—but is symbolic without funding and could exacerbate stigma or emphasize enforcement over treatment.

1. senate

The resolution highlights and supports law‑enforcement successes that can reduce lethal drug supply and protect crops, but it prioritizes enforcement over treatment, may increase taxpayer costs, and raises civil‑liberties concerns for vulnerable communities.

1. senate

The bill broadens naloxone access, education, and awareness—measures that can quickly save lives and reduce stigma—but requires public spending, may face local resistance, and does not substitute for needed investments in long-term treatment and prevention.

1. senate

The resolution raises awareness and improves data collection about fentanyl threats—helpful for prevention and targeting responses—but risks stigmatizing youth and increasing public alarm without providing new funding or concrete treatment and harm-reduction commitments.

1. senate

The bill increases congressional control and oversight to reduce undeclared or prolonged military involvement and limit military escalation in counternarcotics, but those restraints raise the risk of slower executive responses, greater political uncertainty for deployed forces, and potentially higher spending on drug‑interdiction without assured results.

1. senate
3. house
5. president

The bill explicitly brings podiatric medicine programs into existing education/training provisions and makes that change retroactive to Dec 29, 2022—helping students and institutions avoid coverage gaps and reducing statutory ambiguity, while modestly increasing concerns about controlled-substance access for trainees and creating some compliance paperwork/uncertainty.

1. senate
3. house
5. president

The bill centralizes and strengthens federal efforts to disrupt synthetic‑opioid supply chains and coordinate prevention/treatment—potentially saving lives and improving enforcement efficiency—while raising notable costs, civil‑liberty and privacy risks, diplomatic friction, and local compliance/burden concerns that will require careful oversight and safeguards.

1. senate
3. house
5. president

This bill increases federal funding, public‑health preparedness, Medicaid and primary‑care supports, and major transparency and oversight of drug pricing and PBM practices to improve access and accountability—at the tradeoff of substantial new reporting and compliance burdens, privacy and proprietary risks, possible market consolidation, and higher federal outlays that could raise costs for some providers, plans, and taxpayers.

1. senate
3. house
5. president

The bill strengthens U.S. tools and targeted reporting to disrupt foreign-linked fentanyl and methamphetamine supply chains and freeze illicit finance, but does so at the cost of increased diplomatic and economic risk, reduced transparency, and legal/administrative uncertainties for businesses and agencies.

1. senate
3. house
5. president

The bill channels multi-year funding and personnel to strengthen fentanyl interdiction and prosecutions, improving law-enforcement capacity and data-driven responses while raising trade-offs on federal spending, potential resource diversion, prosecutorial disruption, and civil-liberties risks.

1. senate
3. house
5. president

The bill extends emergency scheduling for fentanyl analogues to keep dangerous substances off the street and preserve law-enforcement and rapid-control tools, but it restricts research access and raises compliance and enforcement costs for institutions and taxpayers.

1. senate
3. house
5. president

The bill increases predictability, transparency, and modest centralized support for pediatric research and rare‑disease flexibility, but it also reduces some FDA enforcement leverage and creates administrative shifts that risk slower or reduced pediatric evidence generation and greater uncertainty for clinicians, families, and providers.

1. senate
3. house
5. president

The bill significantly strengthens overdose detection, harm‑reduction access, school preparedness, and treatment flexibility through federal funding and data coordination, while creating privacy risks, ongoing state/local costs, and potential shifts toward criminal investigations and regulatory complexity.

1. senate
3. house
5. president

The bill strengthens U.S. leverage to deter and punish chemical/biological misuse through faster, targeted sanctions and suspension authorities while increasing risks of diplomatic retaliation, economic disruption to businesses and research, and added fairness and resource challenges for the executive branch.

1. senate
3. house
5. president

The bill increases government authority to interdict fentanyl and expedite immigration enforcement—potentially reducing fentanyl flow and easing port backlogs—but does so at the cost of restricting migrants' access to protections, raising civil‑liberties and justice concerns, and risking a shift of resources from treatment to enforcement.

1. senate
3. house
5. president